Publications by authors named "M Nomdedeu"
Background: V617F-mutated myeloproliferative neoplasms (MPN) exhibit abnormal proliferation of bone marrow progenitors and increased risk of thrombosis, specifically in splanchnic veins (SVT). The contribution of the endothelium to the development of the prothrombotic phenotype was explored.
Material And Methods: Plasma and serum samples from V617F MPN patients with (n=26) or without (n=7) thrombotic debut and different treatments, were obtained (n=33).
Reduced Dose of Post-Transplant Cyclophosphamide with Tacrolimus for the Prevention of Graft-versus-Host Disease in HLA-Matched Donor Peripheral Blood Stem Cell Transplants: A Prospective Pilot Study.
Cancers (Basel)
July 2024
PTCY 50 mg/kg/day on days +3/+4 is an excellent strategy to prevent GVHD. However, its use is associated with adverse outcomes such as delayed engraftment, increased risk of infection, and cardiac complications. This pilot study evaluates the efficacy and toxicity of a reduced dose of PTCY (40 mg/kg/day) combined with tacrolimus in 22 peripheral blood HLA-matched alloHSCT patients.
View Article and Find Full Text PDFGenomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology.
Ann Hematol
March 2024
Article Synopsis
- This study examined the impact of splanchnic vein thrombosis (SVT) on prognosis and survival in patients with polycythemia vera (PV) or essential thrombocythemia (ET), comparing those with SVT at diagnosis to a matched control group.
- Findings revealed that a majority of patients with SVT at diagnosis had a specific genetic mutation (JAK2), but this group also showed a significantly higher risk of death and lower event-free survival compared to controls.
- The research indicated that the timing of SVT development (at diagnosis vs. follow-up) influences molecular risk factors, highlighting the importance of genetic testing for better assessing thrombotic risks and disease progression in younger patients with PV/ET.
Post-Transplantation Cyclophosphamide and Tacrolimus for Graft-versus-Host Disease Prevention after Allogeneic Hematopoietic Cell Transplantation from HLA-Matched Donors Has More Advantages Than Limitations.
Transplant Cell Ther
February 2024
This study compared the efficacy of graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide (PTCy) and tacrolimus (Tac) versus other regimens in 272 adults undergoing peripheral blood (PB) allogeneic hematopoietic cell transplantation (allo-HCT) from HLA-matched donors. Of these 272 patients, 95 (34.9%) received PTCy/Tac.
View Article and Find Full Text PDF